Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type 1-infected patients

AIDS Research and Human Retroviruses

Volumn 23, Issue 2, 2007, Pages 216-223

  Gathe Jr , Joseph C ^a   Pierone, Gerald ^b   Piliero, Peter ^c,i   Arasteh, Keikawus ^d   Rubio, Rafael ^e   Lalonde, Richard G ^f   Cooper, David ^g   Lazzarin, Adriano ^h   Kohlbrenner, Veronika M ⁱ   Dohnanyi, Catherine ⁱ   Sabo, John ⁱ   Mayers, Douglas ⁱ  

^a Therapeutic Concepts   (United States)

^b Treasure Coast Infectious Disease Consultants   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d Vivantes Auguste Viktoria Klinikum   (Germany)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; VIRUS ISOLATION; VIRUS LOAD; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRIDINES; PYRONES; RITONAVIR; TREATMENT OUTCOME;

EID: 33947244561     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0178     Document Type: Article

References (23)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Volberding PA: HIV therapy in 2003: Consensus and controversy. AIDS 2003;17(Suppl. 1):S4-S11.
3. Porter K, Babiker A, Bhaskaran K, et al.: CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267-1274.
4. Richman DD, Morton SC, Wrin T, et al.: The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18: 1393-1401.
5. Cane P, Chrystie I, Dunn D, et al., for the UK Group on Transmitted HIV Drug Resistance: Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2006;332:179-180. [Epub 2005 Nov. 18 BMJ doi:10.1136/bmj.38665.534595.55.]
6. Phillips AN, Dunn D, Sabin C, et al., for the UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group: Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487-494.
7. Turner SR, Strohbach JW, Tommasi RA, et al.: Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998;41:3467-3476.
8. Thaisrivongs S and Strohbach JW: Structure-based discovery of tipranavir disodium (PNU-140690E): A potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 1999;51:51-58.
9. Chong KT and Pagano PJ: In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother 1997;41:2367-2373.
10. Larder BA, Hertogs K, Bloor S, et al.: Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14: 1943-1948.
11. Poppe SM, Slade DE, Chong K-T, et al.: Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997;41:1058-1063.
12. Rusconi S, La Seta Catamancio S, Citterio P, et al.: Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000;44:1328-1332.
13. Back NKT, van Wijk A, Remmerswaal D, et al.: In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 2000;14:101-102.
14. Hall D, McCallister S, Neubacher D, Kraft M, and Mayers DL: Characterization of treatment-emergent resistance mutations in two phase II studies of tipranavir (TPV). Presented at the XII International HIV Drug Resistance Workshop, June 10-14, 2003, Cabo San Lucas, Mexico.
15. McCallister S, Valdez H, Curry K, et al.: Resistance/cross resistance profile of tipranavir and peptidic protease inhibitors in multiple protease inhibitor-experienced patients. J Acquir Immune Defic Syndr 2004;35:376-382.
16. Cahn P and Hicks C: RESIST-1 (R-1) and RESIST-2 (R-2) 48-week meta-analyses demonstrate superiority of protease inhibitor (PI) tipranavir + ritonavir (TPV/R) over an optimized comparator PI (CPI/R) regimen in antiretroviral (ARV) experienced patients. Presented at the 10th European AIDS Conference (EACS), November 17-20, 2005, Dublin, Ireland.
17. Curry R, Markowitz M, Slater L, et al.: Safety and efficacy of tipranavir, a non-peptidic protease inhibitor, in multiple PI-failure patients (BI 1182.2). Presented at the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment, July 8-11, 2001, Buenos Aires, Argentina. Abstract 3.
18. Cooper D, Hall D, Jayaweera D, et al.: Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). Presented at the 10th Conference on Retroviruses and Opportunistic Infections (CROI), February 10-14, 2003. Abstract 596.
19. Neubacher D, Markowtiz M, Slater L, Curry R, and McCallister S: Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2). Presented at the 9th European AIDS Conference (EACS), 1st EACS Resistance & Pharmacology Workshop, October 26-29, 2003, Warsaw, Poland.
20. Schwartz R, Kazanjian P, Slater L, et al.: Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/r) in multiple PI-failure patients (BI 1182.2). Presented at the 9th Conference for Retroviruses and Opportunistic Infections, February 24-28, 2002, Seattle, WA.
21. Plosker G and Noble S: Indinavir: A review of its use in the management of HIV infection. Drugs 1999;58:1165-1203.
22. Cvetkovic RS and Goa KL: Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2003;63:769-802.
23. Gartland M, AVANTI Study Group: AVANTI 3: A randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir Ther 2001;6:127-134.